Richard Klausner Buys 158,000 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Richard Klausner acquired 158,000 shares of Lyell Immunopharma stock in a transaction on Friday, March 14th. The shares were bought at an average price of $0.60 per share, for a total transaction of $94,800.00. Following the purchase, the director now owns 843,365 shares of the company’s stock, valued at $506,019. This represents a 23.05 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Lyell Immunopharma Stock Performance

Shares of NASDAQ LYEL opened at $0.58 on Thursday. Lyell Immunopharma, Inc. has a 1 year low of $0.48 and a 1 year high of $3.15. The firm has a market cap of $171.76 million, a price-to-earnings ratio of -0.74 and a beta of -0.41. The stock’s 50-day simple moving average is $0.62 and its 200-day simple moving average is $0.89.

Lyell Immunopharma (NASDAQ:LYEL) last announced its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The business had revenue of $0.01 million for the quarter. As a group, research analysts predict that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $1.00 target price on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Institutional Trading of Lyell Immunopharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC increased its holdings in Lyell Immunopharma by 312.7% in the third quarter. Barclays PLC now owns 240,615 shares of the company’s stock valued at $332,000 after buying an additional 182,315 shares during the last quarter. SG Americas Securities LLC increased its holdings in Lyell Immunopharma by 102.8% in the fourth quarter. SG Americas Securities LLC now owns 116,748 shares of the company’s stock valued at $75,000 after buying an additional 59,182 shares during the last quarter. Jane Street Group LLC increased its holdings in Lyell Immunopharma by 63.7% in the third quarter. Jane Street Group LLC now owns 287,717 shares of the company’s stock valued at $397,000 after buying an additional 111,917 shares during the last quarter. State Street Corp increased its holdings in Lyell Immunopharma by 1.9% in the third quarter. State Street Corp now owns 3,889,553 shares of the company’s stock valued at $5,368,000 after buying an additional 71,233 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in Lyell Immunopharma in the third quarter valued at about $52,000. 66.05% of the stock is owned by institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.